Business · 20/09/2006Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Avastin Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the review period for Pfizer's patent extension application for Avastin, a human biological product, as required by law.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →